Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with invasive cancer that has been confirmed or is suspected to have started in the gastrointestinal (digestive) tract — this includes cancers of the esophagus, stomach junction, stomach, small intestine, a part of the digestive system called the ampulla of Vater, appendix, colon, rectum, or cancers where the starting point is unknown but the digestive tract is suspected
• People at any stage of their cancer for whom a chemotherapy regimen called FOLFOX is considered a standard treatment — whether given before surgery, after surgery, or as an initial treatment
• People who have completed the first day of their first FOLFOX chemotherapy cycle between 1 and 8 days before registering for the trial, with that first cycle including minimum required doses of the chemotherapy drugs oxaliplatin and 5-FU
• People for whom at least four cycles of FOLFOX chemotherapy are planned (each cycle lasts 14 days)
• People aged 18 years or older
• People who are reasonably active and able to carry out daily activities, as measured by a standard medical scale (ECOG performance status of 0, 1, or 2 — confirm with trial site)
• People whose blood counts and organ function meet specific minimum requirements, including white blood cell levels, platelet counts, liver function markers, and kidney function (confirm with trial site for exact values)
• People who are not pregnant and not breastfeeding; women who could become pregnant must have had a negative pregnancy test within 30 days before registering
• People who have had brain metastases (cancer that has spread to the brain), provided they have been treated and follow-up brain scans show no signs of the cancer growing
• People living with HIV, provided they are on effective treatment and their viral load has been undetectable within the past 6 months
• People with a known chronic hepatitis B infection, provided the virus is undetectable in their blood within the past 6 months
• People with a history of hepatitis C infection, provided the virus is undetectable at least 12 weeks after completing antiviral treatment
• People with a known history of heart disease, provided their heart condition is rated as mild (Class I or II on a standard heart health scale — confirm with trial site)

Who may not be able to join:

• People who have previously received systemic (whole-body) treatment for gastrointestinal cancer, other than the first cycle of FOLFOX chemotherapy (prior radiation-sensitising chemotherapy is permitted)
• People who needed preventive white blood cell growth factor injections during their first FOLFOX cycle due to a high risk of fever and low white blood cell counts
• People who have had a serious allergic reaction to oxaliplatin, other platinum-based drugs, the chemotherapy drug fluorouracil (5-FU), or leucovorin
• People with a known inherited condition called congenital long QT syndrome, which affects heart rhythm
• People with a known deficiency of an enzyme called DPD (dihydropyrimidine dehydrogenase), which affects how the body processes certain chemotherapy drugs

Important: Always verify eligibility with the trial site directly before applying.